We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QNBK:QSEQatar National Bank QPSC Analysis

Data as of 2026-03-10 - not real-time

QAR 18.77

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Qatar National Bank trades at a PE of ~10.8, well below the industry average of 17.3, and offers a 4.0% dividend yield with a payout ratio around 41%. The stock sits just above its 200‑day SMA (18.6) but below the 20‑day (19.4) and 50‑day (19.6) averages, while the RSI of 44 indicates neutral momentum. Technical signals are mixed: a bearish MACD and price near the identified support of 17.89 suggest short‑term pressure, yet volume is increasing and the Fear & Greed Index shows “Extreme Greed,” implying market optimism. Analysts rate the stock as a strong buy with a median target of 22.7 QAR, implying roughly a 21% upside from the current 18.77 QAR price.
Fundamentally, QNBK delivers robust profitability (operating margin ~68%, profit margin ~49%) and solid ROE (~14.5%), though operating cash flow is negative, raising a modest question on dividend sustainability. Overall, the valuation appears attractive, the dividend attractive, and the upside potential significant, but investors should watch cash‑flow trends and short‑term technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near technical support at 17.89 QAR
  • Bearish MACD histogram indicating short‑term downside pressure
  • High dividend yield providing cushion despite cash‑flow concerns

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation discount versus peers (PE 10.8 vs 17.3)
  • Analyst consensus strong‑buy with ~21% upside
  • Steady earnings growth (13% revenue growth) and strong profitability

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable market position in Qatar and regional banking footprint
  • Attractive dividend yield combined with low beta (0.21) for defensive profile
  • Undervalued metrics (PB 1.66) and long‑term upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth13.00%
Profit Margin48.92%
P/E Ratio10.8
ROE14.55%
ROA1.29%
P/B Ratio1.7
Op. Cash FlowQAR-105378234368
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI43.7
SupportQAR 17.89
ResistanceQAR 20.42
MA 20QAR 19.41
MA 50QAR 19.62
MA 200QAR 18.61
MACDBearish
VolumeIncreasing
Fear & Greed Index78.29

Valuation

Target PriceQAR 22.82
Upside/Downside21.58%
GradeUndervalued
TypeBlend
Dividend Yield4.03%

Risk Assessment

Beta0.21
Volatility28.57%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.